OCS · Oculis Holding AG
$12.94
+0.12 (+0.94%)
At close · Aug 14
Market Cap
$718.53M
Shares
55.53M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.94
Open$12.84
Day$12.52–13.09
52W close$10.71–32.65
Avg vol 30d320K
Short int1.5M · 2.6% float · 4.7d
Short vol42%
Last earningsNov 5, 2026
DataMay 2021–Aug 2026
Up next
Next earnings call
Nov 5, 2026
Scheduled
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−40%
below
Price vs 50-day avg
+7%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−55%
trailing
YTD return
−35%
this year
Relative strength
−69%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.63% of float · ▼ -2.9% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 3-yr high, broad support
Squeeze score
48
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−40%
Bearish
Price vs 50-day avg
+7%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $12 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.63% of float · ▼ -2.9% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
64 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $13 · 10%
Range high $33
vs 200-day avg -40%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCS
this stock
Oculis Holding AG
|
$718.53M | -35.2% | — | — | 2.6% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCS | +2.1% | +6.2% | -54.8% | +14.4% | -35.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.7% | +1.7% | -68.6% | +10.5% | -49.1% |
Key facts
CIK
1953530
CUSIP
H5870P102
13F (30d)
61 filings
61 filers
Visit website
Investor relations